Founder and Chief Growth Officer of Cybin, Paul Glavine is driven to revolutionize mental health treatment through psychedelic-based therapies. Paul has led the late-stage biotech firm through significant milestones, including securing substantial capital, and earning breakthrough therapy designations from the FDA.

Paul spearheaded a multinational phase 3 program evaluating CYB003 in the treatment of Major Depressive Disorder (MDD), setting the stage for potential regulatory approval. Driven by Paul’s visionary leadership and commitment to expanding Cybin’s therapeutic pipeline, the company has also advanced CYB004 through preclinical trials to human trials for generalized anxiety disorder.